Core Insights - Novo Nordisk is entering the oral GLP-1 market with its new pill, which may provide an opportunity to gain market share despite not dramatically changing the competitive landscape [2][3] - The success of Novo's pill will depend on its manufacturing capabilities and the ability to meet demand, as the active ingredient requires significantly more quantity compared to injectables [4][5][6] - Consumer preferences will be tested in 2026, determining whether they favor the convenience of a pill over the effectiveness of injectables [7][8][9] Manufacturing and Supply - Novo has begun manufacturing the active ingredient for its pill in North Carolina, but there are concerns about its ability to meet demand due to the complexity of the molecule [4][5] - The pill formulation requires approximately 70 times more of the active ingredient to be effective compared to injectable forms, which poses additional manufacturing challenges [6] Market Dynamics - The introduction of Novo's pill and Eli Lilly's upcoming orforglipron will create a competitive environment where consumer preferences will play a crucial role [3][7] - Eli Lilly has demonstrated effective marketing strategies with its own products, which may influence consumer choices in the market [8][9]

随着我国生物医药产业竞争力与创新活力持续攀升，2025创新药高质量发展大会上国家医保局披露最新数据显示，年内中国批准上市的创新药 已达69个，超过去年全年的48个，再次创下历史新高。当前，中国医药产业规模已位居全球第二，创新药在研数目约占全球的30%。 2025年，我国创新药领域掀起了前所未有的BD热潮，不仅印证了中国医药资产在全球范围内性价比与核心竞争力的提升，更推动行业迈入"创 新兑现+全球布局"的关键发展期。 《21世纪》：2025年中国创新药BD交易金额突破千亿美元，你如何看待这一"爆发式增长"的可持续性？这种增长是否已从单纯的"规模扩 张"转向"价值深化"？ 于建林：2025年中国首次超越美国成为全球最大授权来源国，全球TOP20跨国药企中90%已与中国创新药管线开展合作，中国占全球授权交易 近一半。 但也应注意，中国FIC占比仍偏低，源头创新不足。当下BD大部分仍集中在早期授权，临床后期项目交易占比不到一半，从而损失后期巨额收 益。仅少数头部企业（如百济神州、恒瑞医药）具备全链条出海能力，多数企业还是依赖"借船出海"。 这一高质量发展态势的背后，离不开政策的持续赋能，也得益于我国创新药企的深耕加码 ...

The S&P 500 (SNPINDEX:^GSPC) rose 0.46% to 6,909.79 near record territory, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 0.57% to 23,561.84 on tech and healthcare strength, and the Dow Jones Industrial Average (DJINDEX: ^DJI) edged up 0.16% to 48,442.41 in quiet holiday trading. Market movers Obesity-drug leader Novo Nordisk (NYSE:NVO) advanced on FDA approval of its Wegovy pill, lifting healthcare sentiment, while software giant ServiceNow (NYSE:NOW) slid nearly 3% after unveiling a $7.75 billion deal ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Achievers List. Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact Several of the largest US and European drugmakers struck agreements with President Donald Trump on December 19 to voluntarily lower the prices of certain medicines. The move comes as the administration pushes to tie US drug prices more closely to lower costs overseas. Bristol-Myers Squibb Company (NYSE:BMY) was part o ...

Hello and welcome to Market Domination. I'm Josh Lipton live from our New York headquarters. It's just an hour to go here until the closing bell and stocks are higher.That's after data showed the US economy expanded at the fastest pace in two years. You've got the Dow up about 75 points. The S&P 500, your broad gauge, that's up about 4/10en of a percent, rising for a fourth straight day there. Your tech heavy NASDAQ, that's up about half a percent.Well, the delayed reading of third quarter economic growth u ...

The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss. ...

Core Insights - The total addressable market for GLP-1 pills is significant, with over 100 million Americans affected by obesity, indicating a large potential user base for these medications [2][3] - The transition from injectable to oral forms of GLP-1 drugs is expected to increase accessibility and adoption among patients who dislike injections, potentially leading to a higher uptake of these treatments [2][3] Market Dynamics - Novo Nordisk is currently leading the market with its GLP-1 drug, while Eli Lilly is expected to follow closely behind, likely launching its product a few months later [3][4] - The competitive landscape is characterized by a rush to enroll patients before Eli Lilly's product becomes available, as established users may be reluctant to switch medications once they start seeing results [4] Efficacy and Health Impact - Both Novo Nordisk and Eli Lilly's drugs are anticipated to be effective in promoting weight loss and improving related health conditions, with Eli Lilly's product potentially offering slightly better results [5] - A significant increase in the number of users, particularly among those who avoid injections, could lead to improved health outcomes and potentially lower healthcare costs in the long term, despite initial higher expenses associated with these drugs [5][7] Long-term Outlook - The initial phase may see increased healthcare costs due to the high price of these medications, but the long-term health benefits could lead to improved longevity and overall health for the population [6][7] - The focus of these drugs is primarily on health improvement rather than cost reduction, emphasizing the importance of enhancing quality of life and longevity for users [8]

Core Viewpoint - Can-Fite BioPharma Ltd. has announced a 1-for-3,000 reverse split of its ordinary shares, which will take effect on January 2, 2026, with the first trading of the consolidated shares on January 5, 2026 [1][4]. Share Structure Changes - Each outstanding 3,000 pre-split ordinary shares will combine into one new ordinary share automatically, with no action required from shareholders [2]. - The ratio of ordinary shares underlying the Company's American Depositary Shares (ADSs) will change from 1 ADS representing 300 ordinary shares to 1 ADS representing 2 ordinary shares, effective January 5, 2026 [2][3]. - The total number of outstanding ordinary shares will decrease from 42 billion to 14 million as a result of the reverse split [4]. Impact on ADS Holders - For ADS holders, the ratio change equates to a one-for-twenty ADS split, requiring the exchange of every 20 ADSs for one new ADS [3]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [6]. Ownership and Voting Power - The reverse split and ADS ratio change will not affect shareholders' percentage ownership or voting power, aside from minimal effects from fractional shares [5]. Market Expectations - The ADS price is expected to increase proportionally due to the change in the ADS ratio, although there is no assurance that the price will be equal to or greater than twenty times the pre-split price [7]. Company Overview - Can-Fite BioPharma Ltd. is focused on developing small-molecule drugs for oncological and inflammatory diseases, with its lead drug candidate, Piclidenoson, in Phase III trials for psoriasis [8]. - The company is also advancing Namodenoson, which is in various stages of trials for liver cancer and has received Orphan Drug Designation in the U.S. and Europe [8].

On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.NYSE : NVONovo NordiskToday's Change( 7.42 %) $ 3.57Current Price$ 51.67Key Data PointsMarket Cap$162BDay's Range$ 51.05 - $ 53.2052wk Range$ 43.08 - $ 93.80Volume2.1MAvg Vol16MGross Margin81.93 %Dividend Yield3.59 %Novo Nordisk (NVO +7.42%), which develops and markets diabetes and obesity treatments, closed Tuesday’s session at $51.61, up 7.30% after U.S. approval of its once-d ...

Core Viewpoint - Theralase Technologies Inc. has successfully closed a non-brokered private placement offering, raising approximately $CAN 1,334,650 to support its clinical study and general corporate purposes [1][2][3]. Group 1: Offering Details - The company issued a total of 7,850,882 Units at a price of $CAN 0.17 per Unit, resulting in gross proceeds of about $CAN 1,334,650 [2]. - Each Unit consists of one common share and one common share purchase warrant, with the warrant allowing the holder to acquire an additional common share at an exercise price of $CAN 0.21 for five years [2]. - A finder's fee of $31,658 was paid, which included $15,470 in cash and $16,188 in common shares, along with the issuance of 186,221 non-transferable finder warrants [4]. Group 2: Use of Proceeds - The proceeds from the financing will be utilized to advance the Phase II Non-Muscle Invasive Bladder Cancer clinical study, as well as for working capital and general corporate purposes [3]. Group 3: Regulatory and Compliance Information - All securities issued under the Offering will be subject to a four-month and one-day hold period, expiring on April 24, 2026, and the Offering is pending final acceptance from the TSX Venture Exchange [6].